Strategies and Approaches to Optimize Your Clinical Immuno-Oncology Development
MVA Good Morning Meeting
Precision and Immuno-Oncology drug development is being optimized through well-defined preclinical and clinical strategies focused on safety, endpoints and biomarker targets. Evolutions in the regulatory framework, a deeper understanding of cancer and re-defining key endpoints for success in Immuno-Oncology and Precision Medicine are combining to de-risk development.
This event – designed for C-level Executives, Heads of Development, Pre-clinical & Clinical Operations leadership – will be focused on development strategies to support the more rapid movement from preclinical studies to the clinical phase of the development. Key learnings and takeaways on trial design concepts and biomarker considerations for optimizing development strategy, as well as Go / No-Go decisions for agents in the preclinical space, regulatory framework considerations and accelerating the development of new precision and IO therapies.
In addition to the planned presentations, attendees will be able to network with peers and other industry thought leaders dedicated to bringing critical new therapies to cancer patients in need.
Detailed program
For program and more information, please visit the event website: